News >

Screening Continues to Evolve in Prostate Cancer

Danielle Bucco
Published: Monday, Jan 29, 2018

Marc A. Bjurlin, DO

Marc A. Bjurlin, DO
Optimal screening in prostate cancer remains a work in progress, notes Marc A. Bjurlin, DO, particularly with the utilization of active surveillance and prostate-specific antigen (PSA) testing shifting due to updated collaborative guidelines from ASCO, AUA, ASTRO, and SUO released in 2017.

on Genitourinary Cancers, Bjurlin, a clinical assistant professor in the Department of Urology, NYU Langone’s Perlmutter Cancer Center, discussed ongoing efforts to optimize prostate cancer screening.

OncLive: Please discuss your presentation.

Bjurlin: The way that we screen and detect prostate cancer has changed significantly over the last several years. Traditionally, we have screened men with PSA serum blood tests and have found that there is quite a low specificity for detecting prostate cancer. As a result, we had an overdiagnosis and overtreatment of low-grade prostate cancer that [may] never hurt a patient or affect their longevity. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication